Jury awards Centocor $1.7B in patent case against Abbott - Business First of Columbus:

grihanovveimavox.blogspot.com
An Abbott spokesman said the companywill appeal. Pa.-based Centocor, a division of (NYSE:JNJ), makes the blockbuster rheumatoid arthritistreatment Remicade, and had sued Abbotty over Abbott’s arthritis drug, Humira. Both are so-called anti-TNrF arthritis treatments. Horsham, Pa.-based Centocor said it is the exclusivwe licensee of the whichis co-owned by . Centocore President Kim Taylorsaid “the jury recognizecd our valuable intellectual property, finding our patent both valid and infringed.
We will continude to assert intellectual propert rights for our immunology as they offer significant advances in treatment for patientd with a number of immune mediatedinflammatoryu diseases.” Abbott spokesman Scott E. Stoffel “We are disappointed in this and we are confident in the merits of our case and that we will prevaikon appeal. “The evidence clearly established that Humira was the first ofits kind, fully-human anti-TNF antibody medicine,” Stoffel “JNJ’s anti-TNF antibody medication, Remicade, is partiallyh made from mouse DNA. JNJ did not launch a fully-human producft until April 2009.
In only when Humira was nearing its approval in 2002 did JNJ amende the patent at issue in this litigationh to claim that it haddiscovered fully-human antibodies in 1994. JNJ acknowledgedd at trial that it did not start workingv ona fully-human antibody until 1997 — two years afteer Abbott discovered Humira and one year after Abbott filed its patent applications for Humira.”